Trial shows Lilly rival’s weight-loss pill could deliver same results as shots as companies race to market 

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00
Total annual spending on GLP-1 drugs increased by more than 500% in five years, from $13.7 billion in 2018 to $71.7 billion in 2023. (Adobe stock image)

Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get the shot version, fueling new optimism that oral GLP-1 drugs could expand an already enormous market.

The Danish pharmaceutical giant said patients who were obese or overweight and who “adhered to treatment” lost an average of 16.6% of their body weight taking the pill daily over 64 weeks, compared with a placebo group that lost only 2.7%.

“This was comparable with previous trial results of injectable Wegovy,” Novo Nordisk said in a statement Wednesday, a key finding after recent clinical trial results have suggested weight-loss pills may not be as potent as GLP-1 shots on the market such as Wegovy and Eli Lilly and Co.’s Zepbound.

Novo Nordisk shares were up more than 6% by mid-morning Thursday.

Eli Lilly and Novo Nordisk are vying for supremacy in the weight-loss market they dominate as they both race to get an obesity pill to market. Novo Nordisk sought approval for its pill with the Food and Drug Administration earlier this year and expects the agency to conclude its review by the end of this year.

Eli Lilly said last month that it expects to seek approval of its weight-loss pill, orforglipron, this year. Also Wednesday, Eli Lilly released initial results of a clinical trial comparing orforglipron with select doses of oral semaglutide, the active ingredient in Wegovy, saying that its weight-loss pill showed superior reductions in blood-sugar levels and weight. The trial evaluated 1,698 adults with Type 2 diabetes.

Novo Nordisk tested a higher dose of semaglutide in its pill in its clinical trial, involving 307 adults who were overweight or obese. The company said that even for participants who didn’t fully take it as directed, they still lost an average of 13.6% of their body weight, compared with 2.2% for those that got a placebo. Nearly a third of participants who got the Wegovy pill lost at least 20% of their weight regardless of whether they took it exactly as intended, the company said.

In addition to losing weight, participants who got the drug also were able to be more active and improve their cardiovascular risk, Novo Nordisk said.

Like the shot versions, the weight-loss pills come with significant side effects. Novo Nordisk said nearly half of patients who got the Wegovy pill had nausea and nearly a third reported vomiting, though it described such reactions as “generally mild to moderate in severity and transient.” About 7% of participants who got the Wegovy pill dropped out of the trial due to side effects, compared with 6% who got a placebo.

Eli Lilly said that about 10% of participants who received the highest dose of orforglipron dropped out of its trial over side effects, compared with 2.6% who got a placebo.

Even considering the side effects and potency of orforglipron, “it will still be a mega-blockbuster drug,” David Risinger, an analyst at Leerink Partners, wrote in a note to clients Wednesday, estimating that if approved the drug could fetch $14 billion in sales in 2030.

Ahead of decisions by the FDA, both Novo Nordisk and Eli Lilly are readying production for their weight-loss pills, having been unable to keep up with demand for their shots that exploded in popularity.

“Pending FDA approval, ample supply will be available to meet the expected U.S. demand,” Martin Holst Lange, Novo Nordisk’s chief scientific officer, said in the company’s statement.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In